Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the company’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the completion of the transaction, the executive vice president owned 45,172 shares in the company, valued at approximately $23,631,280.08. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

United Therapeutics Trading Down 1.5%

Shares of NASDAQ UTHR traded down $7.88 during midday trading on Friday, reaching $513.12. 414,570 shares of the stock were exchanged, compared to its average volume of 490,770. The stock has a 50 day moving average price of $533.74 and a 200-day moving average price of $537.53. The company has a market capitalization of $22.01 billion, a P/E ratio of 18.36, a P/E/G ratio of 1.79 and a beta of 0.59. United Therapeutics Corporation has a 52-week low of $302.19 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the prior year, the firm posted $6.41 earnings per share. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Bank of America decreased their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Royal Bank Of Canada reduced their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. JPMorgan Chase & Co. raised their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Finally, TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Leuthold Group LLC grew its position in shares of United Therapeutics by 41.4% during the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after buying an additional 3,126 shares during the last quarter. UBS Group AG lifted its holdings in United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after acquiring an additional 70,445 shares during the last quarter. Nicholas Investment Partners LP lifted its holdings in United Therapeutics by 478.5% in the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock worth $2,218,000 after acquiring an additional 3,766 shares during the last quarter. M&T Bank Corp boosted its stake in United Therapeutics by 171.6% in the fourth quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock valued at $1,531,000 after acquiring an additional 1,985 shares during the period. Finally, Seven Fleet Capital Management LP acquired a new position in United Therapeutics in the fourth quarter valued at approximately $633,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.